Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: dendritic cell targeted vaccines - Lipotek

Drug Profile

Research programme: dendritic cell targeted vaccines - Lipotek

Alternative Names: Antigen-encoded DNA vaccines - Lipotek; Lipokel; Lipovax-Fg115-cancer; Lipovax-Fg115-malaria; Lipovax-Fg115-TB; Lipovax-FliC-TB; Lipovaxin; Lipovaxin-TB; R4 - Lipotek

Latest Information Update: 28 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lipotek
  • Class Bacterial vaccines; Cancer vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer; Malaria; Tuberculosis

Most Recent Events

  • 28 Dec 2022 Discontinued - Preclinical for Tuberculosis in Australia (Parenteral)
  • 28 Dec 2022 Discontinued for Cancer in Australia (Parenteral)
  • 28 Dec 2022 Discontinued for Malaria in Australia (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top